Abstract
Adoptive transfer of T cells specific for antigens expressed on tumor cells is an attractive strategy for producing targeted and long-lived anti-tumor activity. T cell therapies have shown activity in selected clinical applications but broader application is limited by inadequate persistence of transferred T cells and by tumor-evasion strategies. Current research focuses on defining the optimum type of cell for transfer, genetically modifying infused T cells to augment function and overcome tumor evasion strategies and modulating the host environment.
Original language | English (US) |
---|---|
Pages (from-to) | 251-257 |
Number of pages | 7 |
Journal | Current Opinion in Immunology |
Volume | 22 |
Issue number | 2 |
DOIs | |
State | Published - Apr 2010 |
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology